According to the news reporter, her journey towards getting a diagnosis for her condition was not easy -- a predicament that ...
HONG KONG, Jan. 5, 2026 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food ...
The FDA has approved GenEditBio's IND application for the CLARITY trial of GEB-101 for TGFBI corneal dystrophy. TGFBI corneal dystrophy results from mutations in the TGFBI gene, causing protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results